SAN DIEGO, Dec. 5, 2012 /PRNewswire/ -- Accelrys, Inc.
(NASDAQ: ACCL), a leading provider of scientific innovation
lifecycle management software, is pleased to announce that the
German Cancer Research Center (Deutsches Krebsforschungszentrum,
DKFZ) has licensed the server-based, on-premises version of the
Contur Electronic Lab Notebook (ELN). The licensing agreement
follows a successful two-month pilot program involving twenty
chemists and biologists in four departments at DKFZ. When fully
implemented, the Contur ELN will accelerate scientific innovation
by improving collaboration, quality, efficiency and security for up
to 1,000 researchers across the largest biomedical research
institute in Germany.
(Logo:
http://photos.prnewswire.com/prnh/20120416/MM88629LOGO)
"We wanted to deploy a single ELN across all scientific
researchers to replace paper, facilitate information sharing and
protect intellectual property," said Holger
Haas, Head of the IT Department, DKFZ. "The single ELN
system reduces cost of ownership while improving the management and
reuse of information, as opposed to individual groups selecting and
deploying different ELNs. Of all the ELNs we assessed, the Contur
ELN was a clear leader because of its ease of use, its proven
deployment track record and the excellent support we received from
Accelrys during the pilot."
Along with increased competition for grants, academic
researchers today face increasingly stringent data sharing and
protection requirements, often imposed by funding organizations.
Scientists also require a common research environment that supports
distributed research teams and external partners while ensuring IP
transparency, accountability and security.
"DKFZ's strategic decision reflects a growing trend in academic
and research organizations today," said Mollie Hunter, Senior Vice President of Sales
and Services at Accelrys. "In terms of rapid deployment, proven
capabilities and bottom-line affordability, the Contur ELN is now
well established as a valuable productivity tool for academic
communities, offering proven performance for thousands of users. An
ELN can pay for itself by preventing just one failed experiment or
unnecessary repeated experiment."
Available as both a server-based, on-premises installation and
as a software-as-a-service offering in the Cloud for Macs and PCs,
the easy-to-deploy-and-use Contur ELN helps academic organizations
meet the sophisticated requirements of today's research
environment. In addition, the scalability of the Contur ELN
accommodates the continually changing workflow and resourcing
requirements encountered in academia.
For more information on deploying the Contur ELN in an academic
environment, read the case study describing the adoption of a
centralized ELN by three Swedish universities or view an on-demand
webinar describing the Karolinska
Institute's strategic approach to implementing a
university-wide ELN. For more information on the Contur ELN, visit
www.accelrys.com/products/eln/contur.
About the German Cancer Research Center
The German Cancer Research Center (Deutsches
Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is
the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists
investigate how cancer develops, identify cancer risk factors and
endeavor to find new strategies to prevent people from getting
cancer. They develop novel approaches to make tumor diagnosis more
precise and treatment of cancer patients more successful. Jointly
with Heidelberg University Hospital, DKFZ has established the
National Center for Tumor Diseases (NCT) Heidelberg where promising
approaches from cancer research are translated into the clinic. The
staff of the Cancer Information Service (KID) offers information
about the widespread disease of cancer for patients, their
families, and the general public. The center is a member of the
Helmholtz Association of National Research Centers. Ninety percent
of its funding comes from the German Federal Ministry of Education
and Research and the remaining ten percent from the State of
Baden-Wurttemberg.
About Accelrys, Inc.
Accelrys (NASDAQ:ACCL), a leading provider of scientific
innovation lifecycle management software, supports industries and
organizations that rely on scientific innovation to differentiate
themselves. The industry-leading Accelrys Enterprise Platform
provides a broad, flexible scientific solution optimized to
integrate the diversity of science, experimental processes and
information requirements across the research, development, process
scale-up and early manufacturing phases of product development. By
incorporating capabilities in applications for modeling and
simulation, enterprise lab management, workflow and automation, and
data management and informatics, Accelrys enables scientific
innovators to access, organize, analyze and share data in
unprecedented ways, ultimately enhancing innovation, improving
productivity and compliance, reducing costs and speeding time from
lab to market.
Accelrys solutions are used by more than 1,300 companies in the
pharmaceutical, biotechnology, energy, chemicals, aerospace,
consumer packaged goods and industrial products industries.
Headquartered in San Diego,
Calif., Accelrys employs more than 200 full-time PhD
scientists. For more information about Accelrys, visit
www.accelrys.com.
SOURCE Accelrys, Inc.